Omrix Biopharmaceuticals Inc.

Ethicon, Gmbh

Depuy Synthes Products, Inc.

Roberto Meidler

Israel Nur

Liliana Bar

Oleg Belyaev

Elena Grimberg

Yonit Tiberman

Anne J Gorman

Nadav Orr

Nadav Ashkenazy

Sridevi N Dhanaraj

Anthony J Kihm

Charito S Buensuceso

Roee Atlas

Roni Mintz

Guanghui Zhang

Ashley DeAnglis

Sanyog Manohar Pendharkar

Tamar Auerbach-Nevo

Nina Raver-Shapira

Ashley De Anglis

Anne Jessica Gorman

Lilliana Bar

The present invention is directed to devices having a substance receiving portion and a membrane constituting the bottom of the substance receiving portion and having such a structure as to allow fluid disposed in the substance receiving portion to be transferred therefrom through the membrane when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence and/or quantify of clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.

Device and process for sample preparation

Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Thrombin solution and methods of use thereof

The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.

Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.

Plasma-supplemented formulation

Provided is a method, device and system for an in-situ preparation of a sample, for example, for use in detecting the presence of, and/or quantifying, clottable fibrinogen in such a sample.

A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

Protein assay

The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.

Immunoglobulin reduced in thrombogenic agents and preparation thereof

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease by systemic administration of umbilical derived cells are disclosed.

Treatment of peripheral vascular disease using umbilical cord tissue-derived cells

The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Reinforced absorbable multilayered hemostatis wound dressing

The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.

Method for removing a lytic enzyme from a heterogeneous mixture

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.

Growing community of inventors

Rehovot, Israel

Roberto Meidler